. Author manuscript; available in PMC: 2012 Oct 1.

Published in final edited form as: Ann Surg Oncol. 2011 Sep 9;18(11):3079–3087. doi: 10.1245/s10434-011-2002-y

Table 3.

Patient #	MRI tumor size (post-biopsy)	Pathology tumor size (post-RFA)
01	1.5 cm	No Residual
02	2.4 cm Enhancement	1.3 cm but non-viable
03	0.9 cm	0.9 cm (IDC)/1 cm DCIS but non-viable
04	-	No Residual
05	-	No Residual - atypia
06	1.2 cm	2.5 cm — Non-Viable
07	Possible Minimal Residual	No Residual
08	1 cm	< 1 cm — Non-Viable
09	0.66 cm	No residual
10	1cm	0.8 cm — Non-Viable
11	1 cm	0.5 cm — Non-Viable
12	Minimal Residual Enhancement Seen	No Residual
13	2 cm Enhancement	Residual Focus — Non-Viable
14	Mild Enhancement Seen	0.2 cm — Non-Viable
15	Thin Rim of Enhancement	No Residual